RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Strategies for the drug discovery...I thought they did a decent job with the debt financing. Good cancer data, if they have it, will make for a better equity financing this time around. It is just a matter of how well they optimize the situation. They need to build investor anticipation regarding TH-1902's prospects. By t he time they do the deal, investors should be falling over themselves to get a piece of it. That normally does not happen with a dump of good news just before the offering as investors need to be up to speed on the company and totally bought in.
Biobob wrote: Biotech financing is like a match of pocker. A lot of campanies have won with poor hands whereas other like Th have failed to do good deals with strong hands...